Drug Profile

Rabusertib

Alternative Names: IC-83; LY2603618

Latest Information Update: 02 Aug 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Array BioPharma; ICOS Corporation
Developer Eli Lilly and Company
Class Antineoplastics; Morpholines; Pyrazines; Small molecules; Urea compounds
Mechanism of Action Checkpoint kinase 1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

30 Jul 2019 Array Biopharma has been acquired by Pfizer
01 Jul 2016 Eli Lilly and Company completes its Phase-I trial for Solid tumours in Japan (NCT01341457)
26 Apr 2013 Discontinued - Phase-I/II for Pancreatic cancer (Combination therapy, Late-stage disease) in Poland (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com